出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年10月
Research Antibodies & Reagents Market – Global forecast to 2028
研究用抗体および試薬市場 : 製品 [抗体 (タイプ、形態、ソース、研究分野)、試薬]、技術 (ウェスタンブロット、フローサイトメトリー、ELISA)、用途 (プロテオミクス、ゲノミクス)、エンドユーザー (製薬、バイオテクノロジー、CRO) 、地域別 – 2028年までの世界予測
Research Antibodies & Reagents Market by Product (Antibodies (Type, Form, Source, Research Area), Reagents), Technology (Western blot, Flow Cytometry, ELISA), Application (Proteomics, Genomics), End User (Pharma, Biotech, CROs) & Region – Global forecast to 2028
| ページ数 | 385 |
| 図表数 | 530 |
| 種別 | 英文調査報告書 |
| 価格 |
Report Overview
The global research antibodies and reagents market is projected to reach USD 16.2 billion by 2028 from USD 11.8 billion in 2023, at a CAGR of 6.5% during the forecast period of 2023 to 2028. The growth of this market can be attributed life science companies that are helping university researchers by providing technical and financial assistance to commercialize university research projects. Also, Antibodies play a significant role in biomarker identification and validation as they are used to detect various antigens, enzymes, DNA, and mRNAs using technologies such as ELISA, electrophoresis, and fluorescence assays that are based on conventional immunoassays. Moreover, developing various separation techniques, advanced protein identification, and structure determination technologies has enabled thousands of proteins to be identified from complex mixtures. This has created significant demand for research antibodies for biomarker identification and validation applications.
On the basis of source, the mice segment holds the highest market share during the forecast period.
Based on the source, the research antibodies market has been categorized into rabbits, mice, and others. Mice accounted for the largest share of the global research antibodies market, by source, in 2022. Mice have traditionally been the host of choice to produce monoclonal antibodies and as a second host against primary rabbit antibodies. These animals offer the advantage of easy production compared to animal use and economic considerations. Such cost-effectiveness of mice as a primary source of antibodies makes this segment the higher share holder.
On the basis of technology, the flow cytometry segment is expected to register the highest CAGR during the forecast period.
On the basis of technology, the research antibodies and reagents market is segmented into western blotting, flow cytometry, ELISA, Immunohistochemistry, Immunofluorescence, Immunoprecipitation, and other technologies. During the forecast period the flow cytometry segment is expected to witness the highest growth. One of the major advantages of flow cytometry technique is its ability to perform simultaneous multi-parameter analysis on single cells within a heterogeneous mixture. It offers a high throughput and the automated quantification of cell features. These factors, along with technological innovations in flow cytometry and its growing applications in cancer research, are driving the growth of this segment.
On the basis of application, the proteomics holds the highest market share during the forecast period.
On the basis of application, the research antibodies and reagents market is segmented into proteomics, drug development and Genomics. In 2022, Proteomics held the largest share of the global research antibodies and reagents market. The increasing importance of proteomic studies in various fields (such as cancer biology, developmental and stem cell biology, and medicine) and the need for the remedial treatment of life-threatening diseases (such as respiratory infections, neurological conditions, and tuberculosis) have led many government agencies to promote proteomics research actively, thus promoting market growth.
On the basis of end user, the pharmaceutical & biotechnology holds the second highest market share during the forecast period.
The research antibodies and reagents market is divided into the pharmaceutical & biotechnology companies, research laboratories and Contract Research Organizations. In 2022 the pharmaceutical & biotechnology companies held the second largest share of the global research antibodies and reagents end-user market as pharmaceutical & biotechnology companies require antibodies for prognostic, predictive, or diagnostic identification and the quantification of biomarkers in drug discovery and development.
By Region, The Asia Pacific region is expected to register the highest CAGR during the forecast period.
During the forecast period (2023 to 2028), the Asia Pacific research antibodies and reagents market is expected to grow at the highest CAGR. Owning to high growth potential, many manufacturers are extending their global manufacturing bases to the APAC. With their low-cost manufacturing advantage, manufacturers consider China and India the most profitable manufacturing and R&D locations. This is contributing to high growth rate in the Asia Pacific region.
Break of primary participants was as mentioned below:
• By Respondant – Supply Side–70%, Demand Side–30%
• By Designation – Manger–45%, CXOs and Directors–30%, Executives–25%
• By Region – North America–30%, Europe–25%, Asia Pacific–30%, Latin America- 10%, Middle East and Africa–5%
Key players in the research antibodies and reagents market
Some prominent players in the global research antibodies and reagents market are Abcam plc (UK), Cell Signaling Technology, Inc. (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), BD (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US), Danaher (US), Lonza (Switzerland), GenScript (China), Revvity (US), SouthernBiotech (US), Illumina, Inc. (US), ImmunoPrecise Antibodies Ltd (US), Fujirebio (Sweden), Analytik Jena GmbH+Co. KG (Germany), Omega Bio-tek, Inc. (US), Dovetail Genomics (US), Atlas Antibodies (Sweden), Rockland Immunochemicals, Inc. (US), Santa Cruz Biotechnology, Inc.(US), Jackson ImmunoResearch Inc. (US), Proteintech Group, Inc. (US), and ICL, Inc. (US).
Research Coverage:
The report analyzes the research antibodies and reagent market and aims at estimating the market size and future growth potential of this market based on various segments such as product, distribution channel, and region. The report also includes a product portfolio matrix of various research antibodies and reagents products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Key Benefits of buying the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.
This report provides insights into the following pointers:
• Analysis of key drivers (Rising funding for life sciences research, Increasing industry-academia collaborations, Growing applications of biomarker identification & validation), restraint (Quality concerns and inadequacy of reproducible results, Ethical concerns for animal welfare in antibody production), opportunities (High-growth potential of emerging economies, Rising demand for personalized medicine and protein therapeutics, Growth in stem cell and neurobiology research, Outsourcing of services to CROs), challenges (Complexities associated with antibody development, Increasing pricing pressure).
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global research antibodies and reagent market. The report analyzes this market by product and distribution channel.
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global research antibodies and reagent market.
• Market Development: Comprehensive information on the lucrative emerging markets by product and distribution channel
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global research antibodies and reagent market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global research antibodies and reagent market.
Table of Contents
1 INTRODUCTION 54
1.1 STUDY OBJECTIVES 54
1.2 MARKET DEFINITION 54
1.2.1 INCLUSIONS AND EXCLUSIONS 55
1.2.2 MARKETS COVERED 56
FIGURE 1 RESEARCH ANTIBODIES AND REAGENTS MARKET 56
1.2.3 YEARS CONSIDERED 56
1.3 CURRENCY CONSIDERED 57
1.4 STAKEHOLDERS 57
1.5 LIMITATIONS 57
1.6 SUMMARY OF CHANGES 57
1.6.1 RECESSION IMPACT 58
2 RESEARCH METHODOLOGY 59
2.1 RESEARCH APPROACH 59
FIGURE 2 RESEARCH DESIGN 59
2.1.1 SECONDARY DATA 60
2.1.2 PRIMARY DATA 61
FIGURE 3 BREAKDOWN OF PRIMARIES 61
2.2 MARKET SIZE ESTIMATION 62
FIGURE 4 MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS) FOR 2022 62
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS METHODOLOGY 63
FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 63
FIGURE 7 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2022) 64
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 65
FIGURE 8 MARKET VALIDATION FROM PRIMARY SOURCES 65
FIGURE 9 TOP-DOWN APPROACH 66
2.3 MARKET GROWTH RATE PROJECTIONS 67
FIGURE 10 CAGR PROJECTIONS 67
FIGURE 11 RESEARCH ANTIBODIES AND REAGENTS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 68
2.4 DATA TRIANGULATION AND METHODOLOGY APPROACH 69
FIGURE 12 DATA TRIANGULATION METHODOLOGY 69
2.5 RESEARCH ASSUMPTIONS 70
2.6 RISK ANALYSIS 70
2.7 RECESSION IMPACT ANALYSIS 71
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH) 71
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 72
TABLE 3 US HEALTH EXPENDITURE, 2023–2028 (USD MILLION) 72
3 EXECUTIVE SUMMARY 73
FIGURE 13 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 73
FIGURE 14 RESEARCH ANTIBODIES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 74
FIGURE 15 RESEARCH REAGENTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 74
FIGURE 16 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 75
FIGURE 17 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 76
FIGURE 18 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 76
FIGURE 19 GEOGRAPHIC SNAPSHOT OF RESEARCH ANTIBODIES AND REAGENTS MARKET 77
4 PREMIUM INSIGHTS 79
4.1 RESEARCH ANTIBODIES AND REAGENTS MARKET OVERVIEW 79
FIGURE 20 RISING FUNDING INVESTMENTS IN LIFE SCIENCES RESEARCH TO DRIVE MARKET GROWTH DURING FORECAST PERIOD 79
4.2 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION 80
FIGURE 21 PROTEOMICS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 80
4.3 GEOGRAPHIC GROWTH OPPORTUNITIES 81
FIGURE 22 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 81
4.4 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY REGION 81
FIGURE 23 ASIA PACIFIC SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 81
4.5 RESEARCH ANTIBODIES AND REAGENTS MARKET: DEVELOPED VS. EMERGING MARKETS 82
FIGURE 24 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD 82
5 MARKET OVERVIEW 83
5.1 INTRODUCTION 83
5.2 MARKET DYNAMICS 83
FIGURE 25 RESEARCH ANTIBODIES AND REAGENTS MARKET: DRIVERS, OPPORTUNITIES, RESTRAINTS, AND CHALLENGES 83
TABLE 4 RESEARCH ANTIBODIES AND REAGENTS MARKET: IMPACT ANALYSIS 84
5.2.1 DRIVERS 84
5.2.1.1 Rising funding for life sciences research 84
5.2.1.2 Increasing industry-academia collaborations 85
5.2.1.3 Growing applications of biomarker identification & validation 86
5.2.2 RESTRAINTS 86
5.2.2.1 Quality concerns and inadequacy of reproducible results 86
5.2.2.2 Ethical concerns for animal welfare in antibody production 87
5.2.3 OPPORTUNITIES 87
5.2.3.1 High-growth potential of emerging economies 87
5.2.3.2 Personalized medicine and protein therapeutics 88
5.2.3.3 Growth in stem cell and neurobiology research 89
5.2.3.4 Outsourcing services to CROs 89
5.2.4 CHALLENGES 90
5.2.4.1 Complexities associated with antibody development 90
5.2.4.2 Increasing pricing pressure 90
5.3 INDUSTRY TRENDS 91
5.3.1 GROWING R&D ON THERAPEUTIC ANTIBODIES 91
5.3.2 OPTIMAL USAGE OF RECOMBINANT ANTIBODIES 91
5.4 SUPPLY CHAIN ANALYSIS 92
FIGURE 26 RESEARCH ANTIBODIES AND REAGENTS MARKETS: SUPPLY SIDE ANALYSIS 93
5.5 PRODUCT PORTFOLIO ANALYSIS 94
TABLE 5 RESEARCH ANTIBODIES AND REAGENTS MARKET: PRODUCT PORTFOLIO ANALYSIS 94
5.6 TECHNOLOGY ANALYSIS 94
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 97
FIGURE 27 REVENUE SHIFT AND REVENUE GROWTH 97
5.8 PRICING ANALYSIS 98
5.8.1 INDICATIVE PRICING ANALYSIS, BY ANTIBODIES 98
TABLE 6 INDICATIVE PRICING OF ANTIBODIES, BY KEY PLAYERS (2022) 98
5.8.2 INDICATIVE PRICING ANALYSIS OF OVERALL MARKET (QUALITATIVE ANALYSIS) 98
5.9 TRADE ANALYSIS (HS CODES) 99
TABLE 7 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS (HS CODE 3822), 2018–2022 (USD THOUSAND) 99
TABLE 8 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS (HS CODE 3822), 2018–2022 (USD THOUSAND) 100
5.10 ECOSYSTEM ANALYSIS 101
5.10.1 ROLE IN ECOSYSTEM 101
5.11 PATENT ANALYSIS 102
FIGURE 28 RESEARCH ANTIBODIES AND REAGENT MARKET: PATENT ANALYSIS 102
TABLE 9 INDICATIVE LIST OF PATENTS IN RESEARCH ANTIBODIES AND REAGENTS MARKET 103
5.12 KEY CONFERENCES AND EVENTS 104
TABLE 10 RESEARCH ANTIBODIES AND REAGENTS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023−2024) 104
5.13 REGULATORY ANALYSIS 105
5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 106
TABLE 11 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 106
5.14 PORTER’S FIVE FORCES ANALYSIS 107
TABLE 12 RESEARCH ANTIBODIES AND REAGENTS MARKET: PORTER’S FIVE FORCES ANALYSIS 107
5.14.1 THREAT OF NEW ENTRANTS 107
5.14.2 THREAT OF SUBSTITUTES 107
5.14.3 BARGAINING POWER OF SUPPLIERS 107
5.14.4 BARGAINING POWER OF BUYERS 107
5.14.5 INTENSITY OF COMPETITIVE RIVALRY 107
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 108
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RESEARCH ANTIBODY & REAGENT PRODUCTS 108
FIGURE 30 BUYING CRITERIA FOR PRODUCTS, BY END USER 108
6 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT 109
6.1 INTRODUCTION 110
TABLE 13 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 110
6.2 REAGENTS 110
TABLE 14 REAGENTS, BY TYPE AND APPLICATION 111
TABLE 15 RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 112
TABLE 16 RESEARCH REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 113
TABLE 17 NORTH AMERICA: RESEARCH REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 18 EUROPE: RESEARCH REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 19 ASIA PACIFIC: RESEARCH REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 20 LATIN AMERICA: RESEARCH REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 21 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
6.2.1 MEDIA & SERA 115
6.2.1.1 Critical component in cell culture to boost demand 115
TABLE 22 RESEARCH REAGENTS MARKET FOR MEDIA & SERA, BY REGION, 2021–2028 (USD MILLION) 115
TABLE 23 NORTH AMERICA: RESEARCH REAGENTS MARKET FOR MEDIA & SERA, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 24 EUROPE: RESEARCH REAGENTS MARKET FOR MEDIA & SERA, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 25 ASIA PACIFIC: RESEARCH REAGENTS MARKET FOR MEDIA & SERA, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 26 LATIN AMERICA: RESEARCH REAGENTS MARKET FOR MEDIA & SERA, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 27 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR MEDIA & SERA, BY COUNTRY, 2021–2028 (USD MILLION) 117
6.2.2 STAINS & DYES 117
6.2.2.1 Growing applications in cell biology and molecular studies to fuel uptake 117
TABLE 28 RESEARCH REAGENTS MARKET FOR STAINS & DYES, BY REGION, 2021–2028 (USD MILLION) 118
TABLE 29 NORTH AMERICA: RESEARCH REAGENTS MARKET FOR STAINS & DYES, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 30 EUROPE: RESEARCH REAGENTS MARKET FOR STAINS & DYES, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 31 ASIA PACIFIC: RESEARCH REAGENTS MARKET FOR STAINS & DYES, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 32 LATIN AMERICA: RESEARCH REAGENTS MARKET FOR STAINS & DYES, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 33 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR STAINS & DYES, BY REGION, 2021–2028 (USD MILLION) 120
6.2.3 FIXATIVES 120
6.2.3.1 High utilization in immunohistochemistry and western blotting to propel market 120
TABLE 34 RESEARCH REAGENTS MARKET FOR FIXATIVES, BY REGION, 2021–2028 (USD MILLION) 120
TABLE 35 NORTH AMERICA: RESEARCH REAGENTS MARKET FOR FIXATIVES, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 36 EUROPE: RESEARCH REAGENTS MARKET FOR FIXATIVES, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 37 ASIA PACIFIC: RESEARCH REAGENTS MARKET FOR FIXATIVES, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 38 LATIN AMERICA: RESEARCH REAGENTS MARKET FOR FIXATIVES, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 39 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR FIXATIVES, BY COUNTRY, 2021–2028 (USD MILLION) 122
6.2.4 BUFFERS 122
6.2.4.1 High utilization in drug development to drive market 122
TABLE 40 RESEARCH REAGENTS MARKET FOR BUFFERS, BY REGION, 2021–2028 (USD MILLION) 123
TABLE 41 NORTH AMERICA: RESEARCH REAGENTS MARKET FOR BUFFERS, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 42 EUROPE: RESEARCH REAGENTS MARKET FOR BUFFERS, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 43 ASIA PACIFIC: RESEARCH REAGENTS MARKET FOR BUFFERS, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 44 LATIN AMERICA: RESEARCH REAGENTS MARKET FOR BUFFERS, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 45 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR BUFFERS, BY COUNTRY, 2021–2028 (USD MILLION) 124
6.2.5 SOLVENTS 125
6.2.5.1 Broad applications in pharmaceutical processes and IHC assays to propel market 125
TABLE 46 RESEARCH REAGENTS MARKET FOR SOLVENTS, BY REGION, 2021–2028 (USD MILLION) 125
TABLE 47 NORTH AMERICA: RESEARCH REAGENTS MARKET FOR SOLVENTS, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 48 EUROPE: RESEARCH REAGENTS MARKET FOR SOLVENTS, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 49 ASIA PACIFIC: RESEARCH REAGENTS MARKET FOR SOLVENTS, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 50 LATIN AMERICA: RESEARCH REAGENTS MARKET FOR SOLVENTS, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 51 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR SOLVENTS, BY COUNTRY, 2021–2028 (USD MILLION) 127
6.2.6 ENZYMES 127
6.2.6.1 Rising proteomic & genomic research studies to fuel uptake 127
TABLE 52 RESEARCH REAGENTS MARKET FOR ENZYMES, BY REGION, 2021–2028 (USD MILLION) 128
TABLE 53 NORTH AMERICA: RESEARCH REAGENTS MARKET FOR ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 54 EUROPE: RESEARCH REAGENTS MARKET FOR ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 55 ASIA PACIFIC: RESEARCH REAGENTS MARKET FOR ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 56 LATIN AMERICA: RESEARCH REAGENTS MARKET FOR ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 57 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 129
6.2.7 PROBES 130
6.2.7.1 Quantitative and versatile capabilities to propel market 130
TABLE 58 RESEARCH REAGENTS MARKET FOR PROBES, BY REGION, 2021–2028 (USD MILLION) 130
TABLE 59 NORTH AMERICA: RESEARCH REAGENTS MARKET FOR PROBES, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 60 EUROPE: RESEARCH REAGENTS MARKET FOR PROBES, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 61 ASIA PACIFIC: RESEARCH REAGENTS MARKET FOR PROBES, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 62 LATIN AMERICA: RESEARCH REAGENTS MARKET FOR PROBES, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 63 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR FIXATIVES, BY COUNTRY, 2021–2028 (USD MILLION) 132
6.2.8 OTHER REAGENTS 132
TABLE 64 OTHER RESEARCH REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 132
TABLE 65 NORTH AMERICA: OTHER RESEARCH REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 66 EUROPE: OTHER RESEARCH REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 67 ASIA PACIFIC: OTHER RESEARCH REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 68 LATIN AMERICA: OTHER RESEARCH REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 69 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR OTHER RESEARCH REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 134
6.3 ANTIBODIES 134
TABLE 70 RESEARCH ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION) 135
TABLE 71 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 72 EUROPE: RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 73 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 74 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 75 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
6.3.1 ANTIBODIES, BY TYPE 137
TABLE 76 ANTIBODIES, BY TYPE AND APPLICATION 137
TABLE 77 RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
6.3.1.1 Primary antibodies 138
6.3.1.1.1 Rising demand for personalized therapeutics to drive market 138
TABLE 78 PRIMARY RESEARCH ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION) 138
TABLE 79 NORTH AMERICA: PRIMARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 80 EUROPE: PRIMARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 81 ASIA PACIFIC: PRIMARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 82 LATIN AMERICA: PRIMARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 83 MIDDLE EAST & AFRICA: PRIMARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 140
6.3.1.2 Secondary antibodies 140
6.3.1.2.1 Low production costs to support market growth 140
TABLE 84 SECONDARY RESEARCH ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION) 141
TABLE 85 NORTH AMERICA: SECONDARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 86 EUROPE: SECONDARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 87 ASIA PACIFIC: SECONDARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 88 LATIN AMERICA: SECONDARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 89 MIDDLE EAST & AFRICA: SECONDARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 143
6.3.2 ANTIBODIES, BY FORM 143
TABLE 90 ANTIBODIES, BY FORM AND APPLICATION 143
TABLE 91 RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 144
6.3.2.1 Monoclonal antibodies 144
6.3.2.1.1 High usage in biomedical science to boost demand 144
TABLE 92 MONOCLONAL RESEARCH ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION) 144
TABLE 93 NORTH AMERICA: MONOCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 94 EUROPE: MONOCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 95 ASIA PACIFIC: MONOCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 96 LATIN AMERICA: MONOCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 97 MIDDLE EAST & AFRICA: MONOCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 146
6.3.2.2 Polyclonal antibodies 146
6.3.2.2.1 Ability to target specific assays to fuel uptake 146
TABLE 98 POLYCLONAL RESEARCH ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION) 147
TABLE 99 NORTH AMERICA: POLYCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 100 EUROPE: POLYCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 101 ASIA PACIFIC: POLYCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 148
TABLE 102 LATIN AMERICA: POLYCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 148
TABLE 103 MIDDLE EAST & AFRICA: POLYCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 148
6.3.2.3 Recombinant antibodies 149
6.3.2.3.1 High usage in cancer treatment to fuel uptake 149
TABLE 104 RECOMBINANT RESEARCH ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION) 149
TABLE 105 NORTH AMERICA: RECOMBINANT RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 149
TABLE 106 EUROPE: RECOMBINANT RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 107 ASIA PACIFIC: RECOMBINANT RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 108 LATIN AMERICA: RECOMBINANT RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 109 MIDDLE EAST & AFRICA: RECOMBINANT RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 151
6.3.3 ANTIBODIES, BY SOURCE 151
TABLE 110 ANTIBODIES, BY SOURCE AND APPLICATION 151
TABLE 111 RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 152
6.3.3.1 Mice 152
6.3.3.1.1 Preferred hosts for antibody production to propel market 152
TABLE 112 MICE ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION) 153
TABLE 113 NORTH AMERICA: MICE ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 114 EUROPE: MICE ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 115 ASIA PACIFIC: MICE ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 154
TABLE 116 LATIN AMERICA: MICE ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 154
TABLE 117 MIDDLE EAST & AFRICA: MICE ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 154
6.3.3.2 Rabbits 155
6.3.3.2.1 Cost-effective benefits to drive demand 155
TABLE 118 RABBIT ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION) 155
TABLE 119 NORTH AMERICA: RABBIT ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 155
TABLE 120 EUROPE: RABBIT ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 121 ASIA PACIFIC: RABBIT ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 122 LATIN AMERICA: RABBIT ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 123 MIDDLE EAST & AFRICA: RABBIT ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 157
6.3.3.3 Other sources 157
TABLE 124 OTHER ANTIBODY SOURCES MARKET, BY REGION, 2021–2028 (USD MILLION) 157
TABLE 125 NORTH AMERICA: OTHER ANTIBODY SOURCES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 157
TABLE 126 EUROPE: OTHER ANTIBODY SOURCES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 127 ASIA PACIFIC: OTHER ANTIBODY SOURCES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 128 LATIN AMERICA: OTHER ANTIBODY SOURCES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 129 MIDDLE EAST & AFRICA: OTHER ANTIBODY SOURCES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 159
6.3.4 ANTIBODIES, BY RESEARCH AREA 159
TABLE 130 ANTIBODIES, BY RESEARCH AREA AND APPLICATION 159
TABLE 131 RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 161
6.3.4.1 Oncology 161
6.3.4.1.1 Rising incidence of cancer and associated oncology diagnostics to drive market 161
TABLE 132 RESEARCH ANTIBODIES MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 162
TABLE 133 NORTH AMERICA: RESEARCH ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 162
TABLE 134 EUROPE: RESEARCH ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 162
TABLE 135 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 136 LATIN AMERICA: RESEARCH ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 137 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 163
6.3.4.2 Infectious diseases 164
6.3.4.2.1 Increasing incidence of viral infections to drive market 164
TABLE 138 RESEARCH ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 164
TABLE 139 NORTH AMERICA: RESEARCH ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 140 EUROPE: RESEARCH ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 141 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 142 LATIN AMERICA: RESEARCH ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 166
TABLE 143 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 166
6.3.4.3 Immunology 166
6.3.4.3.1 Growing awareness of autoimmune diseases to support market growth 166
TABLE 144 RESEARCH ANTIBODIES MARKET FOR IMMUNOLOGY, BY REGION, 2021–2028 (USD MILLION) 167
TABLE 145 NORTH AMERICA: RESEARCH ANTIBODIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 146 EUROPE: RESEARCH ANTIBODIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 147 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 148 LATIN AMERICA: RESEARCH ANTIBODIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 149 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 168
6.3.4.4 Neurobiology 169
6.3.4.4.1 Wide applications in molecular & cellular neuroscience to drive market 169
TABLE 150 RESEARCH ANTIBODIES MARKET FOR NEUROBIOLOGY, BY REGION, 2021–2028 (USD MILLION) 169
TABLE 151 NORTH AMERICA: RESEARCH ANTIBODIES MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 152 EUROPE: RESEARCH ANTIBODIES MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 153 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 154 LATIN AMERICA: RESEARCH ANTIBODIES MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 171
TABLE 155 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 171
6.3.4.5 Stem cells 171
6.3.4.5.1 Growing importance of transplantations to propel market 171
TABLE 156 RESEARCH ANTIBODIES MARKET FOR STEM CELLS, BY REGION, 2021–2028 (USD MILLION) 172
TABLE 157 NORTH AMERICA: RESEARCH ANTIBODIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 172
TABLE 158 EUROPE: RESEARCH ANTIBODIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 173
TABLE 159 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 173
TABLE 160 LATIN AMERICA: RESEARCH ANTIBODIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 173
TABLE 161 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 174
6.3.4.6 Other research areas 174
TABLE 162 RESEARCH ANTIBODIES MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2021–2028 (USD MILLION) 175
TABLE 163 NORTH AMERICA: RESEARCH ANTIBODIES MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 175
TABLE 164 EUROPE: RESEARCH ANTIBODIES MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 175
TABLE 165 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 176
TABLE 166 LATIN AMERICA: RESEARCH ANTIBODIES MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 176
TABLE 167 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 176
7 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY 177
7.1 INTRODUCTION 178
TABLE 168 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 178
7.2 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 178
7.2.1 ABILITY TO DETECT ONCOLOGY AND INFECTIOUS DISEASE SAMPLES TO PROPEL MARKET 178
TABLE 169 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ELISA, BY REGION, 2021–2028 (USD MILLION) 179
TABLE 170 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ELISA, BY COUNTRY, 2021–2028 (USD MILLION) 180
TABLE 171 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ELISA, BY COUNTRY, 2021–2028 (USD MILLION) 180
TABLE 172 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ELISA, BY COUNTRY, 2021–2028 (USD MILLION) 180
TABLE 173 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ELISA, BY COUNTRY, 2021–2028 (USD MILLION) 181
TABLE 174 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ELISA, BY COUNTRY, 2021–2028 (USD MILLION) 181
7.3 FLOW CYTOMETRY 181
7.3.1 GROWING APPLICATIONS IN CANCER RESEARCH TO DRIVE MARKET 181
TABLE 175 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR FLOW CYTOMETRY, BY REGION, 2021–2028 (USD MILLION) 182
TABLE 176 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION) 183
TABLE 177 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION) 183
TABLE 178 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION) 183
TABLE 179 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION) 184
TABLE 180 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION) 184
7.4 WESTERN BLOTTING 184
7.4.1 HIGH ACCURACY AND SIMPLIFIED ASSESSMENT TO DRIVE MARKET 184
TABLE 181 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR WESTERN BLOTTING, BY REGION, 2021–2028 (USD MILLION) 185
TABLE 182 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2028 (USD MILLION) 185
TABLE 183 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2028 (USD MILLION) 186
TABLE 184 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2028 (USD MILLION) 186
TABLE 185 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2028 (USD MILLION) 186
TABLE 186 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2028 (USD MILLION) 187
7.5 IMMUNOFLUORESCENCE 187
7.5.1 ABILITY TO DETERMINE SPECIFIC GENE EXPRESSIONS TO SUPPORT MARKET 187
TABLE 187 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOFLUORESCENCE, BY REGION, 2021–2028 (USD MILLION) 188
TABLE 188 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2021–2028 (USD MILLION) 188
TABLE 189 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2021–2028 (USD MILLION) 188
TABLE 190 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2021–2028 (USD MILLION) 189
TABLE 191 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2021–2028 (USD MILLION) 189
TABLE 192 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2021–2028 (USD MILLION) 189
7.6 IMMUNOHISTOCHEMISTRY 190
7.6.1 GROWING APPLICATIONS IN DRUG EFFICACY TESTING TO SUPPORT MARKET GROWTH 190
TABLE 193 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2021–2028 (USD MILLION) 190
TABLE 194 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2021–2028 (USD MILLION) 191
TABLE 195 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2021–2028 (USD MILLION) 191
TABLE 196 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2021–2028 (USD MILLION) 191
TABLE 197 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2021–2028 (USD MILLION) 192
TABLE 198 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2021–2028 (USD MILLION) 192
7.7 IMMUNOPRECIPITATION 192
7.7.1 HIGH-SPECIFICITY RESULTS TO CONTRIBUTE TO MARKET GROWTH 192
TABLE 199 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOPRECIPITATION, BY REGION, 2021–2028 (USD MILLION) 193
TABLE 200 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOPRECIPITATION, BY COUNTRY, 2021–2028 (USD MILLION) 193
TABLE 201 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOPRECIPITATION, BY COUNTRY, 2021–2028 (USD MILLION) 194
TABLE 202 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOPRECIPITATION, BY COUNTRY, 2021–2028 (USD MILLION) 194
TABLE 203 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOPRECIPITATION, BY COUNTRY, 2021–2028 (USD MILLION) 194
TABLE 204 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOPRECIPITATION, BY REGION, 2021–2028 (USD MILLION) 195
7.8 OTHER TECHNOLOGIES 195
TABLE 205 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION) 196
TABLE 206 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION) 196
TABLE 207 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION) 197
TABLE 208 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION) 197
TABLE 209 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION) 197
TABLE 210 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION) 198
8 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION 199
8.1 INTRODUCTION 200
TABLE 211 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 200
8.2 PROTEOMICS 200
8.2.1 RISING GOVERNMENT INVESTMENTS IN RESEARCH PROJECTS TO DRIVE MARKET 200
TABLE 212 TECHNOLOGICAL APPLICATIONS OF ANTIBODIES IN PROTEOMICS 201
TABLE 213 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PROTEOMICS, BY REGION, 2021–2028 (USD MILLION) 202
TABLE 214 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PROTEOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 202
TABLE 215 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PROTEOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 202
TABLE 216 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PROTEOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 203
TABLE 217 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PROTEOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 203
TABLE 218 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PROTEOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 203
8.3 DRUG DEVELOPMENT 204
8.3.1 RISING PHARMA R&D EXPENDITURE TO PROPEL MARKET 204
FIGURE 31 APPLICATION OF ANTIBODIES IN DRUG DEVELOPMENT PROCESS 204
TABLE 219 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR DRUG DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION) 205
TABLE 220 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 205
TABLE 221 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 206
TABLE 222 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 206
TABLE 223 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 206
TABLE 224 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 207
8.4 GENOMICS 207
8.4.1 INCREASING INVESTMENTS IN GENOMICS MEDICINE TO SUPPORT MARKET GROWTH 207
TABLE 225 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR GENOMICS, BY REGION, 2021–2028 (USD MILLION) 208
TABLE 226 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR GENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 208
TABLE 227 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR GENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 209
TABLE 228 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR GENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 209
TABLE 229 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR GENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 209
TABLE 230 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR GENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 210
9 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER 211
9.1 INTRODUCTION 212
TABLE 231 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 212
9.2 RESEARCH LABORATORIES 212
9.2.1 INCREASING STUDIES IN BIOMEDICAL AND LIFE SCIENCE RESEARCH TO PROPEL MARKET 212
TABLE 232 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR RESEARCH LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 213
TABLE 233 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 213
TABLE 234 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 214
TABLE 235 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 214
TABLE 236 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 214
TABLE 237 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 215
9.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 215
9.3.1 RISING FOCUS ON DRUG DEVELOPMENT TO DRIVE MARKET 215
TABLE 238 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 216
TABLE 239 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 216
TABLE 240 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 217
TABLE 241 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 217
TABLE 242 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 217
TABLE 243 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 218
9.4 CONTRACT RESEARCH ORGANIZATIONS 218
9.4.1 ASSISTED SERVICES FOR MAB DEVELOPMENT TO SUPPORT MARKET GROWTH 218
TABLE 244 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION) 219
TABLE 245 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 219
TABLE 246 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 219
TABLE 247 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 220
TABLE 248 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 220
TABLE 249 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 220
10 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY REGION 221
10.1 INTRODUCTION 222
TABLE 250 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 222
10.2 NORTH AMERICA 222
FIGURE 32 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET SNAPSHOT 223
TABLE 251 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 223
TABLE 252 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 224
TABLE 253 NORTH AMERICA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 224
TABLE 254 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 224
TABLE 255 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 225
TABLE 256 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 225
TABLE 257 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 225
TABLE 258 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 226
TABLE 259 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 226
TABLE 260 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 227
10.2.1 US 227
10.2.1.1 Increasing funding for oncology therapeutics to drive market 227
TABLE 261 US NIH BUDGET FOR DISCIPLINES, FY 2019 TO FY 2022 (USD BILLION) 227
TABLE 262 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 228
TABLE 263 US: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 228
TABLE 264 US: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 229
TABLE 265 US: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 229
TABLE 266 US: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 229
TABLE 267 US: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 230
TABLE 268 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 230
TABLE 269 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 231
TABLE 270 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 231
10.2.2 CANADA 231
10.2.2.1 Rising funding for biomedical research projects to drive market 231
TABLE 271 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 232
TABLE 272 CANADA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 233
TABLE 273 CANADA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 233
TABLE 274 CANADA: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 233
TABLE 275 CANADA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 234
TABLE 276 CANADA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 234
TABLE 277 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 235
TABLE 278 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 235
TABLE 279 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 236
10.2.3 NORTH AMERICA: RECESSION IMPACT 236
10.3 EUROPE 237
TABLE 280 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 237
TABLE 281 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 238
TABLE 282 EUROPE: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 238
TABLE 283 EUROPE: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 238
TABLE 284 EUROPE: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 239
TABLE 285 EUROPE: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 239
TABLE 286 EUROPE: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 239
TABLE 287 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 240
TABLE 288 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 240
TABLE 289 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 241
10.3.1 GERMANY 241
10.3.1.1 Growing industry-academia collaborations for life science research to drive market 241
TABLE 290 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 241
TABLE 291 GERMANY: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 242
TABLE 292 GERMANY: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 242
TABLE 293 GERMANY: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 242
TABLE 294 GERMANY: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 243
TABLE 295 GERMANY: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 243
TABLE 296 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 244
TABLE 297 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 244
TABLE 298 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 245
10.3.2 UK 245
10.3.2.1 Rising incidence of cancer to support market growth 245
TABLE 299 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 246
TABLE 300 UK: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 246
TABLE 301 UK: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 246
TABLE 302 UK: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 247
TABLE 303 UK: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 247
TABLE 304 UK: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 247
TABLE 305 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 248
TABLE 306 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 248
TABLE 307 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 249
10.3.3 FRANCE 249
10.3.3.1 Rising demand for personalized therapeutics to support market growth 249
TABLE 308 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 249
TABLE 309 FRANCE: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 250
TABLE 310 FRANCE: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 250
TABLE 311 FRANCE: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 250
TABLE 312 FRANCE: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 251
TABLE 313 FRANCE: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 251
TABLE 314 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 252
TABLE 315 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 252
TABLE 316 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 253
10.3.4 ITALY 253
10.3.4.1 Federal funding for targeted research projects to support market growth 253
TABLE 317 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 254
TABLE 318 ITALY: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 254
TABLE 319 ITALY: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 254
TABLE 320 ITALY: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 255
TABLE 321 ITALY: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 255
TABLE 322 ITALY: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 255
TABLE 323 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 256
TABLE 324 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 256
TABLE 325 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 256
10.3.5 SPAIN 257
10.3.5.1 Favorable funding initiatives for novel therapeutic development to propel market 257
TABLE 326 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 257
TABLE 327 SPAIN: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 258
TABLE 328 SPAIN: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 258
TABLE 329 SPAIN: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 258
TABLE 330 SPAIN: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 259
TABLE 331 SPAIN: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 259
TABLE 332 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 260
TABLE 333 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 260
TABLE 334 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 260
10.3.6 REST OF EUROPE 261
TABLE 335 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 261
TABLE 336 REST OF EUROPE: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 262
TABLE 337 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 262
TABLE 338 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 262
TABLE 339 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 263
TABLE 340 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 263
TABLE 341 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 264
TABLE 342 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 264
TABLE 343 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 264
10.3.7 EUROPE: RECESSION IMPACT 265
10.4 ASIA PACIFIC 265
FIGURE 33 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET SNAPSHOT 266
TABLE 344 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 267
TABLE 345 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 267
TABLE 346 ASIA PACIFIC: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 267
TABLE 347 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 268
TABLE 348 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 268
TABLE 349 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 268
TABLE 350 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 269
TABLE 351 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 269
TABLE 352 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 270
TABLE 353 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 270
10.4.1 CHINA 270
10.4.1.1 Rising establishment of R&D facilities to propel market 270
TABLE 354 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 271
TABLE 355 CHINA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 271
TABLE 356 CHINA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 272
TABLE 357 CHINA: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 272
TABLE 358 CHINA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 272
TABLE 359 CHINA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 273
TABLE 360 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 273
TABLE 361 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 274
TABLE 362 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 274
10.4.2 JAPAN 274
10.4.2.1 Rising growth in biotechnology industry to propel market 274
TABLE 363 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 275
TABLE 364 JAPAN: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 275
TABLE 365 JAPAN: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 276
TABLE 366 JAPAN: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 276
TABLE 367 JAPAN: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 276
TABLE 368 JAPAN: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 277
TABLE 369 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 277
TABLE 370 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 278
TABLE 371 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 278
10.4.3 INDIA 278
10.4.3.1 Rising growth in pharmaceutical industry to drive market 278
TABLE 372 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 279
TABLE 373 INDIA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 279
TABLE 374 INDIA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 280
TABLE 375 INDIA: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 280
TABLE 376 INDIA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 280
TABLE 377 INDIA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 281
TABLE 378 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 281
TABLE 379 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 282
TABLE 380 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 282
10.4.4 REST OF ASIA PACIFIC 282
TABLE 381 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 283
TABLE 382 REST OF ASIA PACIFIC: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 283
TABLE 383 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 283
TABLE 384 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 284
TABLE 385 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 284
TABLE 386 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 284
TABLE 387 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 285
TABLE 388 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 285
TABLE 389 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 286
10.4.5 ASIA PACIFIC: RECESSION IMPACT 286
10.5 LATIN AMERICA 287
TABLE 390 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 287
TABLE 391 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 287
TABLE 392 LATIN AMERICA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 288
TABLE 393 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 288
TABLE 394 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 288
TABLE 395 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 289
TABLE 396 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 289
TABLE 397 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 290
TABLE 398 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 290
TABLE 399 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 291
10.5.1 BRAZIL 291
10.5.1.1 Growing hub for pharma R&D to support market growth 291
TABLE 400 BRAZIL: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 291
TABLE 401 BRAZIL: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 292
TABLE 402 BRAZIL: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 292
TABLE 403 BRAZIL: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 292
TABLE 404 BRAZIL: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 293
TABLE 405 BRAZIL: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 293
TABLE 406 BRAZIL: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 294
TABLE 407 BRAZIL: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 294
TABLE 408 BRAZIL: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 295
10.5.2 REST OF LATIN AMERICA 295
TABLE 409 REST OF LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 295
TABLE 410 REST OF LATIN AMERICA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 296
TABLE 411 REST OF LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 296
TABLE 412 REST OF LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 296
TABLE 413 REST OF LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 297
TABLE 414 REST OF LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 297
TABLE 415 REST OF LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 298
TABLE 416 REST OF LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 298
TABLE 417 REST OF LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 299
10.5.3 LATIN AMERICA: RECESSION IMPACT 299
10.6 MIDDLE EAST & AFRICA 300
TABLE 418 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 300
TABLE 419 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 300
TABLE 420 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 301
TABLE 421 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 301
TABLE 422 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 301
TABLE 423 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 302
TABLE 424 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 302
TABLE 425 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 303
TABLE 426 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 303
TABLE 427 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 304
10.6.1 MIDDLE EAST 304
10.6.1.1 Rising research collaborations to drive market 304
TABLE 428 MIDDLE EAST: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 304
TABLE 429 MIDDLE EAST: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 305
TABLE 430 MIDDLE EAST: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 305
TABLE 431 MIDDLE EAST: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 305
TABLE 432 MIDDLE EAST: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 306
TABLE 433 MIDDLE EAST: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 306
TABLE 434 MIDDLE EAST: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 307
TABLE 435 MIDDLE EAST: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 307
TABLE 436 MIDDLE EAST: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 308
10.6.2 AFRICA 308
10.6.2.1 Growing genomic studies to support market growth 308
TABLE 437 AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 309
TABLE 438 AFRICA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 309
TABLE 439 AFRICA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 309
TABLE 440 AFRICA: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION) 310
TABLE 441 AFRICA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION) 310
TABLE 442 AFRICA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION) 310
TABLE 443 AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 311
TABLE 444 AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 311
TABLE 445 AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION) 312
10.6.3 MIDDLE EAST & AFRICA: RECESSION IMPACT 312
11 COMPETITIVE LANDSCAPE 313
11.1 OVERVIEW 313
11.2 STRATEGIES ADOPTED BY KEY PLAYERS 314
FIGURE 34 KEY DEVELOPMENTS IN RESEARCH ANTIBODIES AND REAGENTS MARKET 314
11.3 MARKET SHARE ANALYSIS 315
11.3.1 RESEARCH ANTIBODIES AND REAGENTS MARKET: MARKET SHARE ANALYSIS 315
FIGURE 35 MARKET SHARE ANALYSIS FOR OVERALL MARKET, BY KEY PLAYER (2022) 315
TABLE 446 RESEARCH ANTIBODIES AND REAGENTS MARKET: INTENSITY OF COMPETITIVE RIVALRY 315
11.3.2 RESEARCH ANTIBODIES MARKET: MARKET SHARE ANALYSIS (2022) 317
FIGURE 36 RESEARCH ANTIBODIES MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER (2022) 317
11.4 REVENUE SHARE ANALYSIS OF TOP PLAYERS 318
FIGURE 37 REVENUE SHARE ANALYSIS OF TOP PLAYERS (2020–2022) 318
11.5 COMPANY EVALUATION MATRIX 319
11.5.1 STARS 319
11.5.2 EMERGING LEADERS 319
11.5.3 PERVASIVE PLAYERS 319
11.5.4 PARTICIPANTS 319
FIGURE 38 RESEARCH ANTIBODIES AND REAGENTS MARKET: COMPANY EVALUATION MATRIX (2022) 320
11.5.5 COMPANY FOOTPRINT 321
11.5.5.1 Company footprint (25 Companies) 321
TABLE 447 COMPANY FOOTPRINT ANALYSIS 321
11.5.5.2 Company product footprint (25 Companies) 322
TABLE 448 PRODUCT FOOTPRINT ANALYSIS 322
11.5.5.3 Company regional footprint (25 Companies) 323
TABLE 449 REGIONAL FOOTPRINT ANALYSIS 323
11.6 START-UP/SME EVALUATION MATRIX 324
11.6.1 PROGRESSIVE COMPANIES 324
11.6.2 RESPONSIVE COMPANIES 324
11.6.3 DYNAMIC COMPANIES 324
11.6.4 STARTING BLOCKS 324
FIGURE 39 RESEARCH ANTIBODIES AND REAGENTS MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2022) 325
TABLE 450 RESEARCH ANTIBODIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 326
TABLE 451 RESEARCH ANTIBODIES AND REAGENTS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES 327
11.7 COMPETITIVE TRENDS 327
TABLE 452 RESEARCH ANTIBODIES AND REAGENTS MARKET: PRODUCT LAUNCHES (2020−2023) 327
TABLE 453 RESEARCH ANTIBODIES AND REAGENTS MARKET: DEALS (2020−2023) 328
TABLE 454 RESEARCH ANTIBODIES AND REAGENTS MARKET: OTHER DEVELOPMENTS (2020−2023) 329
12 COMPANY PROFILES 330
12.1 KEY PLAYERS 330
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 ABCAM PLC 330
TABLE 455 ABCAM PLC: BUSINESS OVERVIEW 330
FIGURE 40 ABCAM PLC: COMPANY SNAPSHOT (2022) 331
12.1.2 CELL SIGNALING TECHNOLOGY, INC. 337
TABLE 456 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW 337
12.1.3 THERMO FISHER SCIENTIFIC INC. 340
TABLE 457 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 340
FIGURE 41 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 341
12.1.4 MERCK KGAA 346
TABLE 458 MERCK KGAA: BUSINESS OVERVIEW 346
FIGURE 42 MERCK KGAA: COMPANY SNAPSHOT (2022) 347
12.1.5 BECTON, DICKINSON AND COMPANY 350
TABLE 459 BD: BUSINESS OVERVIEW 350
FIGURE 43 BD: COMPANY SNAPSHOT (2022) 351
12.1.6 BIO-RAD LABORATORIES, INC. 354
TABLE 460 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 354
FIGURE 44 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 355
12.1.7 F. HOFFMANN-LA ROCHE LTD. 357
TABLE 461 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 357
FIGURE 45 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 358
12.1.8 AGILENT TECHNOLOGIES, INC. 362
TABLE 462 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 362
FIGURE 46 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2022) 363
12.1.9 DANAHER 366
TABLE 463 DANAHER: BUSINESS OVERVIEW 366
FIGURE 47 DANAHER: COMPANY SNAPSHOT (2022) 367
12.1.10 LONZA GROUP 369
TABLE 464 LONZA GROUP: BUSINESS OVERVIEW 369
FIGURE 48 LONZA GROUP: COMPANY SNAPSHOT (2022) 370
12.1.11 GENSCRIPT 373
TABLE 465 GENSCRIPT: BUSINESS OVERVIEW 373
FIGURE 49 GENSCRIPT: COMPANY SNAPSHOT (2022) 374
12.1.12 REVVITY 376
TABLE 466 REVVITY: BUSINESS OVERVIEW 376
FIGURE 50 PERKINELMER INC.: COMPANY SNAPSHOT (2022) 377
12.1.13 ILLUMINA, INC. 380
TABLE 467 ILLUMINA, INC.: BUSINESS OVERVIEW 380
FIGURE 51 ILLUMINA, INC.: COMPANY SNAPSHOT (2022) 381
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS 384
12.2.1 IMMUNOPRECISE ANTIBODIES LTD. 384
TABLE 468 IMMUNOPRECISE ANTIBODIES LTD.: COMPANY OVERVIEW 384
12.2.2 FUJIREBIO 385
TABLE 469 FUJIREBIO: COMPANY OVERVIEW 385
12.2.3 ANALYTIK JENA GMBH+CO. KG 386
TABLE 470 ANALYTIK JENA GMBH+CO. KG: COMPANY OVERVIEW 386
12.2.4 OMEGA BIO-TEK, INC. 387
TABLE 471 OMEGA BIO-TEK, INC.: COMPANY OVERVIEW 387
12.2.5 DOVETAIL GENOMICS 388
TABLE 472 DOVETAIL GENOMICS: COMPANY OVERVIEW 388
12.2.6 ATLAS ANTIBODIES AB 389
TABLE 473 ATLAS ANTIBODIES AB: COMPANY OVERVIEW 389
12.2.7 ROCKLAND IMMUNOCHEMICALS, INC. 390
TABLE 474 ROCKLAND IMMUNOCHEMICALS, INC.: BUSINESS OVERVIEW 390
12.2.8 SANTA CRUZ BIOTECHNOLOGY, INC. 391
TABLE 475 SANTA CRUZ BIOTECHNOLOGY, INC.: COMPANY OVERVIEW 391
12.2.9 JACKSON IMMUNORESEARCH INC. 392
TABLE 476 JACKSON IMMUNORESEARCH INC.: COMPANY OVERVIEW 392
12.2.10 PROTEINTECH GROUP, INC. 393
TABLE 477 PROTEINTECH GROUP, INC.: COMPANY OVERVIEW 393
12.2.11 ICL, INC. 394
TABLE 478 ICL, INC.: COMPANY OVERVIEW 394
12.2.12 SOUTHERNBIOTECH 395
TABLE 479 SOUTHERNBIOTECH: COMPANY OVERVIEW 395
13 APPENDIX 396
13.1 DISCUSSION GUIDE 396
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 401
13.3 CUSTOMIZATION OPTIONS 403
13.4 RELATED REPORTS 403
13.5 AUTHOR DETAILS 404